Product Description
Mechanisms of Action: NMDA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merz
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Tinnitus|Alzheimer Disease
Phase 2: Multiple Sclerosis|Nystagmus, Pathologic|Nystagmus, Congenital|Tinnitus|Chronic Pain|Cancer Pain|Acute Pain|Pain, Postoperative
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618000298213p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Myopia |
None |
|||
NCT00983099 |
MRZ 92579/NA/1006 | P1 |
Completed |
Healthy Volunteers |
2010-09-01 |
2019-03-19 |
Treatments |
|
NCT01109680 |
MRZ 92579-1048-0 | P1 |
Completed |
Healthy Volunteers |
2010-06-01 |
2019-03-19 |
Treatments |
|
NCT00978614 |
MRZ 92579/TI/1006 | P1 |
Completed |
Healthy Volunteers |
2010-04-01 |
2019-03-19 |
||
NCT00972127 |
MRZ 92579/TI/1004 | P1 |
Completed |
Healthy Volunteers |
2009-12-01 |
2019-03-19 |
Treatments |
|
NCT00936026 |
MRZ 92579/TI/1002 | P1 |
Completed |
Healthy Volunteers |
2009-12-01 |
2019-03-18 |
Treatments |
|
NCT00955760 |
MRZ 92579/TI/1003 | P1 |
Completed |
Healthy Volunteers |
2009-12-01 |
2019-03-18 |
Treatments |
|
NCT00915174 |
MRZ 92579/TI/1005 | P1 |
Completed |
Healthy Volunteers |
2009-11-01 |
2019-03-18 |
Treatments |
|
NCT00712283 |
MRZ 92579-0628/1 | P1 |
Completed |
Healthy Volunteers |
2009-03-01 |
2019-03-18 |
Treatments |
|
2011-004998-83 |
2011-004998-83 | P2 |
Completed |
Unknown |
2013-07-09 |
2022-03-13 |
Treatments |
|
2007-007663-25 |
2007-007663-25 | P2 |
Terminated |
Nystagmus, Congenital |
2010-06-10 |
2022-03-12 |
Treatments |
|
2007-002595-34 |
2007-002595-34 | P2 |
Completed |
Nystagmus, Congenital |
2009-11-06 |
2022-03-12 |
Treatments |
|
2004-002520-18 |
2004-002520-18 | P2 |
Terminated |
Cancer Pain|Chronic Pain |
2007-05-01 |
2022-03-12 |
Treatments |
|
2005-001592-36 |
2005-001592-36 | P2 |
Completed |
Tinnitus |
2007-03-08 |
2022-03-12 |
Treatments |
|
NCT00405886 |
MRZ 92579-0508/1 | P2 |
Completed |
Tinnitus |
2007-03-01 |
2019-03-21 |
||
2004-001782-18 |
pre-emptive Analgesie | P2 |
Completed |
Acute Pain|Pain, Postoperative |
2006-06-30 |
2022-03-12 |
Treatments |
|
NCT00827008 |
OLLTT | P3 |
Terminated |
Tinnitus |
2011-12-01 |
2019-03-18 |
Treatments |
|
2008-001432-13 |
2008-001432-13 | P3 |
Terminated |
Tinnitus |
2011-10-12 |
2025-07-05 |
Treatments |
|
2009-011246-25 |
2009-011246-25 | P3 |
Completed |
Tinnitus |
2011-06-03 |
2022-03-13 |
Treatments |
|
NCT00955799 |
MRZ 92579/TI/3003 | P3 |
Completed |
Tinnitus |
2011-05-01 |
2019-03-18 |
Treatments |
|
2007-007835-16 |
2007-007835-16 | P3 |
Completed |
Tinnitus |
2011-03-19 |
2022-03-12 |
Treatments |
|
2008-000639-16 |
2008-000639-16 | P3 |
Completed |
Tinnitus |
2010-06-22 |
2022-03-12 |
Treatments |
|
NCT00772980 |
MRZ 92579/TI/3002 | P3 |
Completed |
Tinnitus |
2010-06-01 |
2019-03-18 |
Treatments |
|
NCT00739635 |
EASE | P3 |
Completed |
Tinnitus |
2010-02-01 |
2019-03-18 |
||
NCT00090116 |
NER-MD-02 | P3 |
Completed |
Alzheimer Disease |
2005-03-01 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/02/2023 |
PubMed |
Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease. |
|
08/13/2021 |
PubMed |
Efficacy of pharmacologic treatment in tinnitus patients without specific or treatable origin: A network meta-analysis of randomised controlled trials. |
|
10/18/2019 |
News Article |
Global Tinnitus Pipeline Insights 2019 |